Merck.com - Research & Development News
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
This page shows you the latest items in this publication.
66 records returned
Merck Statement on HIV Vaccine Trial
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - September 24, 2009 Category: Pharmaceuticals Source Type: news
New, Long-Term Data for Odanacatib, Merck's Investigational Cat K Inhibitor, Showed Positive Results in Treating OsteoporosisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - September 14, 2009 Category: Pharmaceuticals Source Type: news
Merck Updates Status of Clinical Development Programs for Investigational CGRP Receptor Antagonist Treatments for Acute Migraine; MK-3207 Clinical Development DiscontinuedEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - September 10, 2009 Category: Pharmaceuticals Source Type: news
Merck & Co., Inc. and Portola Enter Worldwide License Agreement to Develop and Commercialize Betrixaban, a Novel Investigational Oral Anticoagulant for Cardiovascular DiseaseEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - July 9, 2009 Category: Pharmaceuticals Source Type: news
Merck & Co., Inc. and Drugs for Neglected DiseasesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - June 22, 2009 Category: Pharmaceuticals Source Type: news
Rolofylline Did Not Demonstrate Efficacy for Acute Heart Failure in Clinical TrialEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - June 5, 2009 Category: Pharmaceuticals Source Type: news
AstraZeneca and Merck & Co., Inc. Form Pioneering Collaboration to Investigate Novel Combination Anticancer RegimenEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - June 1, 2009 Category: Pharmaceuticals Source Type: news
Studies of GARDASIL®, Merck's Cervical Cancer Vaccine, and HPV 16 Vaccine Component of GARDASIL Presented at International Papillomavirus ConferenceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - May 8, 2009 Category: Pharmaceuticals Source Type: news
Merck Announces Interim Phase IIa Study Results of MK-7009, an Investigational Oral Hepatitis C Virus Protease Inhibitor, in Patients with Chronic Hepatitis CEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - April 23, 2009 Category: Pharmaceuticals Source Type: news
Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusive Licensing Agreement for Investigational Monoclonal Antibody Combination for Clostridium Difficile InfectionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - April 21, 2009 Category: Pharmaceuticals Source Type: news
Merck & Co., Inc. and Cardiome Sign License Agreement for Vernakalant, an Investigational Drug for Treatment of Atrial FibrillationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - April 8, 2009 Category: Pharmaceuticals Source Type: news
Phase III Studies Showed ISENTRESS® in Combination Therapy Provided Significant Viral Load Reductions through 96 Weeks in Treatment-Experienced Patients with Triple-Class Resistant HIVEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - February 9, 2009 Category: Pharmaceuticals Source Type: news
Data from ISENTRESS®, Merck's HIV Integrase Inhibitor, in Patients Whose HIV is Controlled on a Lopinavir/Ritonavir-Based Therapy Presented at the 16Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - February 9, 2009 Category: Pharmaceuticals Source Type: news
Merck Announces FDA Acceptance of Supplemental New Drug Application for ISENTRESS® (raltegravir) in Adult Patients Previously Untreated for HIV-1Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - December 12, 2008 Category: Pharmaceuticals Source Type: news
GARDASIL®, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III StudyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - November 13, 2008 Category: Pharmaceuticals Source Type: news
Dynavax and Merck & Co., Inc. Provide Update on U.S. FDA Clinical Hold on Investigational Vaccine HEPLISAV™Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - October 21, 2008 Category: Pharmaceuticals Source Type: news
Researchers to Evaluate a Once-Daily Investigational Dose of Raltegravir, Merck's Integrase Inhibitor, in an Investigational Population, Patients Previously Untreated for HIV-1Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - October 7, 2008 Category: Pharmaceuticals Source Type: news
Merck Discontinues Development of Investigational Medicine Taranabant for ObesityEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - October 2, 2008 Category: Pharmaceuticals Source Type: news
European Commission Adopts European Medicines Agency (EMEA) Recommendations on ARCOXIA™ (etoricoxib) 90 mgEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - September 29, 2008 Category: Pharmaceuticals Source Type: news
Merck & Co., Inc. and Japan Tobacco Inc. Sign Licensing Agreement for Novel Osteoanabolic Drug Candidate to Treat OsteoporosisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - September 25, 2008 Category: Pharmaceuticals Source Type: news
Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Increased Bone Mineral Density (BMD) Over Two Years at Key Fracture Sites in Phase IIB StudyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - September 16, 2008 Category: Pharmaceuticals Source Type: news
Merck & Co., Inc.'s Investigational Migraine Treatment Telcagepant Relieved Migraine Pain and Symptoms in Latest Phase III StudyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - September 6, 2008 Category: Pharmaceuticals Source Type: news
Dynavax and Merck & Co., Inc. Announce Phase 3 Trial with Investigational Hepatitis B Vaccine (HEPLISAV™) Met its Primary EndpointEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - August 5, 2008 Category: Pharmaceuticals Source Type: news
Schering-Plough And Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint VentureEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - June 27, 2008 Category: Pharmaceuticals Source Type: news
Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase III StudyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - June 27, 2008 Category: Pharmaceuticals Source Type: news
Merck Provides Update on U.S. Regulatory Status of MK-0524A (ER niacin/laropiprant) and MK-0524B (ER niacin/laropiprant/simvastatin)Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - June 20, 2008 Category: Pharmaceuticals Source Type: news
Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone MetastasesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - May 27, 2008 Category: Pharmaceuticals Source Type: news
ACHIEVE Imaging Study DiscontinuedEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - May 21, 2008 Category: Pharmaceuticals Source Type: news
Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant)Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - April 28, 2008 Category: Pharmaceuticals Source Type: news
Schering-Plough/Merck Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/MontelukastEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - April 25, 2008 Category: Pharmaceuticals Source Type: news
Two Merck Medicines Recommended for Approval in the European UnionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - April 24, 2008 Category: Pharmaceuticals Source Type: news
Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV™Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - April 17, 2008 Category: Pharmaceuticals Source Type: news
Merck's Investigational Rolofylline Associated with Improved Dyspnea and Preserved Renal Function in Acute Heart Failure Patients in a Phase III Pilot StudyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - April 1, 2008 Category: Pharmaceuticals Source Type: news
Patients Treated with Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE™) Reported Significantly Less Flushing Than Patients Treated with Niaspan™ in Phase III StudyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - March 31, 2008 Category: Pharmaceuticals Source Type: news
Update on ACHIEVE: A Study of Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE™)Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - March 31, 2008 Category: Pharmaceuticals Source Type: news
Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight LossEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - March 31, 2008 Category: Pharmaceuticals Source Type: news
Merck Scientists Apply Innovative Research Method to Identify Changes in Gene Networks Linked to ObesityEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - March 17, 2008 Category: Pharmaceuticals Source Type: news
STEP Study Volunteers to be Informed Whether They Received Vaccine or PlaceboEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - November 13, 2007 Category: Pharmaceuticals Source Type: news
Data from STEP Study Presented at Open Scientific Session Confirm Merck's Investigational HIV Vaccine was not EffectiveEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - November 7, 2007 Category: Pharmaceuticals Source Type: news
GTx, Inc. and Merck & Co., Inc. Enter Global Strategic Collaboration for the Development of SARMs, a Novel Investigational Class of Drugs to Treat Muscle Loss and other Musculoskeletal ConditionsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - November 6, 2007 Category: Pharmaceuticals Source Type: news
Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE™) Coadministered with Simvastatin Had Significant Additive Effects on LDL-C, HDL-C and Triglycerides in Phase III StudyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - November 5, 2007 Category: Pharmaceuticals Source Type: news
DYNAVAX and MERCK & CO., INC. ANNOUNCE PARTNERSHIP TO DEVELOP HEPLISAV™, AN INVESTIGATIONAL HEPATITIS B VACCINE CURRENTLY IN PHASE 3Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - November 1, 2007 Category: Pharmaceuticals Source Type: news
Update regarding clinical trials of Merck's HIV vaccine candidateEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - October 23, 2007 Category: Pharmaceuticals Source Type: news
Statement by Merck & Co., Inc. Regarding FDA Nonprescription Advisory Committee Review of MEVACOR® (lovastatin)Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - October 22, 2007 Category: Pharmaceuticals Source Type: news
Merck's Investigational CETP-Inhibitor, MK-0859 (anacetrapib), Produced Positive Effects on Lipids with No Observed Blood Pressure Changes in Phase IIb StudyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - October 4, 2007 Category: Pharmaceuticals Source Type: news
Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck's Investigational HIV Vaccine CandidateEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - September 21, 2007 Category: Pharmaceuticals Source Type: news
ISENTRESS™ (raltegravir), in Combination with Optimized Background Therapy (OBT), Provided Sustained Viral Suppression in Highly Treatment-Experienced Patients Infected with HIV, through 48 WeeksEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - September 18, 2007 Category: Pharmaceuticals Source Type: news
FDA Advisory Committee Unanimously Recommends Accelerated Approval of ISENTRESS™ (raltegravir), Merck's Investigational Oral Integrase Inhibitor, for Treatment of HIVEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - September 5, 2007 Category: Pharmaceuticals Source Type: news
Merck's Investigational Lipid-Modifier, CORDAPTIVE™ (ER niacin/laropiprant), Positively Affected Key Lipid Parameters With Less Flushing, In Data from Phase III StudyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - September 2, 2007 Category: Pharmaceuticals Source Type: news
Merck Announces FDA Acceptance of NDA for CORDAPTIVE™ (ER niacin/laropiprant), Formerly Known as MK-0524A, an Investigational Lipid-ModifierEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Research & Development News - August 29, 2007 Category: Pharmaceuticals Source Type: news
